The FDA Priority Review for AMT-130 is the key catalyst; watch for the PDUFA decision on May 1, 2027 and any updates on the confirmatory study enrollment. The EPS miss is modest and typical for a pre-revenue biotech; the cash runway removes near-term financing risk.
Drug in focus
QURE drug pipeline →AMT-130
▲ Bullish Named in this press release- Impact
- Phase
- Phase 1/2 (pivotal for accelerated approval)
- Time to market
- BLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)
- Next catalyst
- None dated
What to watchThe BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $23.03entry
- T+1 · 12d ago −8.77%α −4.36% · $21.01
- T+5 · 6d ago +6.75%α +7.66% · $24.59
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The headline event is the FDA's acceptance of the BLA for AMT-130 in Huntington's disease under Priority Review, with a PDUFA date of May 1, 2027, and alignment on a confirmatory study design. Cash of $768.4M funds operations into 2030.
Key Financial Metrics
Key Facts
- FDA granted Priority Review for AMT-130 BLA; PDUFA target May 1, 2027
- Q3 2026 revenue $5.2M vs. consensus $5.4M (beat by 3.7%)
- Cash, equivalents and securities $768.4M as of Sep 30, 2026; runway into 2030
- Confirmatory study design aligned with FDA: ~200 patients, 2:1 randomization, TFC primary endpoint at 36 months; screening starts by end of 2026
- Net loss improved to $61.2M from $80.5M in Q3 2025
Financial Impact
Revenue beat by $0.2M; EPS miss by $0.06; cash position increased by $145.9M from Dec 2025
Risk Factors
- FDA may not approve AMT-130 despite Priority Review; confirmatory study data required for full approval
- Clinical data (cUHDRS p=0.144) showed non-significant slowing; TFC endpoint significant but nominal p-values
- Revenue is minimal and dependent on license fees; no commercial product yet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395189 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Viewing Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers